×
About 101,860 results

LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patien...
https://doi.org/10.1016/j.ijcard.2021.10.024
International Journal of Cardiology; Rizos CV, Skoumas I et. al.

Oct 24th, 2021 - The 2019 European guidelines (ESC/EAS) for the treatment of dyslipidaemias recommend more aggressive targets for low-density lipoprotein cholesterol (LDL-C) in patients with familial hypercholesterolemia (FH). Current lipid-lowering treatment is often inadequate to achieve these targets. Data from the HELLAS-FH registry were analysed to assess achievement of LDL-C targets in adults with FH base...

A human multi-lineage hepatic organoid model for liver fibrosis.
https://doi.org/10.1038/s41467-021-26410-9 10.1055/s-0036-1571295 10.1146/annurev-pathol-011110-130246 10.1016/j.bbadis.2017.07.026 10.1159/000374096 10.3748/wjg.v22.i48.10512 10.1038/nrgastro.2017.38 10.1172/JCI66369 10.1136/gutjnl-2015-309655 10.1038/ncomms3823 10.3109/03008208909103901 10.1172/JCI200112373 10.1542/peds.2013-3646 10.1007/s00467-013-2634-1 10.1056/NEJMra022161 10.1056/NEJMra1010172 10.1038/ng833 10.1086/340448 10.1111/j.1523-1755.2005.00148.x 10.3389/fped.2017.00221 10.1016/j.ymgme.2003.10.010 10.1681/ASN.2007070770 10.1128/MCB.00072-07 10.1152/ajprenal.00341.2007 10.1002/hep.22636 10.1002/hep.26554 10.1172/jci.insight.94954 10.1126/science.aaa1934 10.1038/s41586-018-0393-7 10.1038/s41586-018-0394-6 10.1038/nature21065 10.1016/j.jhep.2019.11.007 10.1097/01.ASN.0000078805.87038.05 10.1016/j.ejmg.2015.12.013 10.1038/nature22403 10.1242/jcs.099697 10.1117/1.3041159 10.1016/j.jhep.2009.12.009 10.1038/s41586-019-1631-3 10.4049/jimmunol.173.10.6409 10.1016/S1074-7613(00)80145-4 10.1016/j.celrep.2014.04.036 10.1073/pnas.1320661111 10.1016/j.neuroscience.2017.09.025 10.1620/tjem.239.251 10.1007/s11523-019-00653-5 10.1016/j.ymgme.2009.11.010 10.1158/0008-5472.CAN-04-2416 10.1080/10409238.2016.1269716 10.1038/ejhg.2016.97 10.1016/j.addr.2017.05.007 10.1055/s-0036-1597816 10.1002/cphy.c120035 10.1016/j.addr.2017.07.004 10.1016/j.addr.2017.05.018 10.1038/nbt.2647 10.1021/jp035693v 10.1109/JSTQE.2009.2032512 10.1117/1.3655353 10.1111/j.1478-3231.2010.02347.x 10.1046/j.1365-2818.1997.1340694.x 10.1038/nbt.4042 10.1038/nbt.4096 10.1093/nar/28.1.27 10.1093/nar/gkv1351 10.1016/j.cell.2019.05.031 10.1186/s13059-019-1663-x 10.1093/bioinformatics/btm254 10.1002/hep.21622 10.1152/ajpgi.00358.2018 10.1073/pnas.0506580102 10.1038/nprot.2015.020 10.1002/cyto.a.22271 10.1093/bioinformatics/btx180 10.1016/j.neuroscience.2012.10.031 10.1016/j.gie.2013.02.037 10.1002/rcm.6656 10.1021/ac900166a
Nature Communications; Guan Y, Enejder A et. al.

Oct 24th, 2021 - To investigate the pathogenesis of a congenital form of hepatic fibrosis, human hepatic organoids were engineered to express the most common causative mutation for Autosomal Recessive Polycystic Kidney Disease (ARPKD). Here we show that these hepatic organoids develop the key features of ARPKD liver pathology (abnormal bile ducts and fibrosis) in only 21 days. The ARPKD mutation increases colla...

Regulation of autophagy as a therapeutic option in glioblastoma.
https://doi.org/10.1007/s10495-021-01691-z 10.22034/APJCP.2018.19.9.2613 10.1056/NEJMoa043330 10.1158/0008-5472.CAN-16-2983 10.1056/NEJMoa043331 10.5732/cjc.013.10207 10.1158/0008-5472.CAN-06-0127 10.1038/nature03128 10.1126/science.1254257 10.1038/nrc3918 10.1093/neuonc/nov164 10.1101/gad.261982.115 10.18388/pb.2018_121 10.1097/NEN.0b013e31823fe8f1 10.1016/j.cell.2013.09.034 10.1007/s00401-015-1432-1 10.1016/B978-0-323-35762-3.00018-4 10.1002/ijc.29990 10.1016/j.brainresbull.2019.09.012 10.3390/ijms15023145 10.1016/j.cmet.2017.04.004 10.1016/S1474-4422(07)70076-5 10.3390/cancers11030312 10.15252/embj.201490784 10.1158/1078-0432.CCR-10-2634 10.1016/j.cell.2013.05.039 10.1038/ncb2788 10.1242/jcs.051011 10.4161/auto.23323 10.1007/s10014-011-0029-1 10.1038/ng.2734 10.1016/j.bbcan.2016.11.003 10.4161/cc.27518 10.1016/j.cell.2009.03.048 10.1080/15548627.2015.1009767 10.1007/s12253-017-0310-7 10.1038/cddis.2013.338 10.1038/nature16187 10.4161/cc.10.8.15330 10.1038/nature09557 10.1038/onc.2012.111 10.1038/sj.cdd.4402030 10.1111/j.1440-1789.2010.01197.x 10.1080/15548627.2015.1009795 10.3171/foc.2006.20.4.4 10.1016/j.cell.2004.11.046 10.1038/nature11287 10.1038/cdd.2014.31 10.1186/1475-2867-13-119 10.1038/bjc.2016.19 10.1016/s0304-419x(03)00004-0 10.1038/sj.cdd.4401359 10.1200/JCO.2008.19.8721 10.1200/JCO.2008.16.3055 10.1093/jjco/hys121 10.1200/JCO.2007.12.2440 10.1158/0008-5472.CAN-06-1010 10.1016/B978-0-323-47660-7.00010-0 10.1016/j.pharmthera.2017.10.017 10.1158/0008-5472.CAN-11-3831 10.1227/NEU.0b013e3182314f9d 10.1016/j.ejphar.2015.12.017 10.1016/j.canlet.2015.02.012 10.4161/auto.28984 10.1016/j.semcancer.2020.05.015 10.1111/bph.14816 10.1038/cddis.2014.467 10.1080/15548627.2015.1056970 10.1007/s11064-019-02802-8 10.1007/s10495-015-1198-x 10.1371/journal.pone.0158537 10.1371/journal.pone.0072882 10.22038/IJBMS.2016.7472 10.1016/j.freeradbiomed.2011.10.487 10.1038/cddis.2014.182 10.1074/jbc.M113.528760 10.1016/j.cbi.2013.06.004 10.18632/oncotarget.11396 10.1158/1055-9965.EPI-07-2917 10.1016/j.cbi.2014.04.017 10.1016/j.canlet.2014.09.039 10.1016/j.bbamcr.2017.05.008 10.1016/B978-0-323-47660-7.00019-7 10.1016/B978-0-12-819609-0.00003-1 10.1016/j.actbio.2019.01.020 10.1016/j.biomaterials.2014.03.041 10.1016/j.bcp.2019.03.023 10.1016/B978-0-323-47660-7.00006-9 10.1001/jama.2015.16669 10.1038/cddis.2017.171 10.1038/nrg1879 10.1074/jbc.M109.080796 10.1007/s11010-013-1835-z 10.1080/15548627.2018.1501133 10.1111/cas.12422 10.4196/kjpp.2011.15.4.211 10.1111/j.1432-1033.1997.0240a.x 10.1016/j.ejca.2012.06.027 10.1186/1748-717X-6-156 10.1097/CAD.0000000000000463 10.1038/cddis.2013.142 10.1158/1078-0432.CCR-14-3147 10.3390/nu8030167 10.1155/2013/596496 10.1016/j.molcel.2015.05.031 10.1080/15548627.2018.1474314 10.18632/oncotarget.4239 10.1016/j.biopha.2019.109339 10.1001/archophthalmol.2010.321 10.3390/ijms19123773 10.1023/a:1008209720526 10.1016/B978-0-323-47660-7.00002-1 10.1016/B978-0-323-47660-7.00003-3 10.1016/j.yexcr.2014.05.011 10.1007/s11060-011-0632-3 10.1002/iub.1445 10.3892/ijo.32.4.829 10.3892/ijo_00000563 10.1074/jbc.270.5.2320 10.1093/neuonc/nov152 10.5732/cjc.011.10234 10.1002/ijc.25975 10.1158/0008-5472.CAN-04-4392 10.1158/0008-5472.CAN-04-3640 10.1038/gt.2008.98 10.1007/s11060-014-1680-2 10.1007/s10637-011-9775-5 10.1038/sj.mt.6300400 10.3390/ijms20020399 10.3892/mmr.2016.4796 10.2147/OTT.S149708 10.1016/j.neulet.2006.08.013 10.1042/BSR20140141 10.1038/bjc.2014.529 10.1158/1541-7786.MCR-09-0562 10.1002/ijc.23648 10.1016/j.nano.2020.102270 10.1039/C8TB03165G 10.1016/j.molmed.2019.11.001 10.1016/j.semcancer.2020.03.010 10.1016/j.canlet.2020.01.034 10.1007/s11060-017-2619-1 10.1073/pnas.79.6.1889 10.1016/S0021-9258(17)37680-9 10.1371/journal.pone.0218972 10.1247/csf.23.33 10.1007/s11060-014-1686-9 10.1016/j.femsyr.2004.07.006 10.1007/BF01051046 10.3171/2015.1.FOCUS14767 10.1093/ons/opz374 10.1002/stem.1335 10.2174/1568009618666180308105048 10.1007/s00109-011-0844-1 10.3390/cells9040857 10.1002/cbin.11137 10.1080/01926230701320337 10.3390/ijms19030889 10.4161/cc.20718 10.1016/j.ejphar.2021.174217 10.4103/1673-5374.276322
Apoptosis : an International Journal on Programmed Cell D... Manea AJ, Ray SK

Oct 24th, 2021 - Around three out of one hundred thousand people are diagnosed with glioblastoma multiforme, simply called glioblastoma, which is the most common primary brain tumor in adults. With a dismal prognosis of a little over a year, receiving a glioblastoma diagnosis is oftentimes fatal. A major advancement in its treatment was made almost two decades ago when the alkylating chemotherapeutic agent temo...

Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor...
https://doi.org/10.1007/s00467-021-05316-0 10.1007/s00467-018-4189-7 10.1038/nrneph.2012.58 10.1007/s00467-020-04486-7 10.1007/s00467-007-0726-5 10.1016/j.ekir.2018.07.021 10.1111/j.1523-1755.2004.00486.x 10.1007/s00467-016-3390-9 10.1681/ASN.2006040347 10.1007/s00467-018-4099-8 10.1136/bmj.n71 10.1111/jebm.12266 10.1136/bmj.l4898 10.1136/bmj.i4919 10.5414/cnp64035 10.1007/s10157-003-0255-x 10.1111/j.1442-200x.2004.01955.x 10.1007/s00467-008-1006-8 10.1177/1470320316647240 10.1067/mpd.2000.103448 10.1111/j.1742-1241.2009.02038.x 10.1007/s10157-013-0921-6 10.1111/j.1742-1241.2012.02970.x 10.1097/00004872-199609002-00001 10.1152/ajpheart.1995.268.6.H2274 10.1016/j.bbrc.2007.04.105 10.1111/j.1440-1681.2009.05172.x 10.1111/j.1751-7176.2011.00508.x 10.1053/j.ajkd.2006.01.017 10.1210/endo-129-2-823 10.1001/archinte.160.5.685
Pediatric Nephrology (Berlin, Germany); Vaz de Castro PAS, Bitencourt L et. al.

Oct 24th, 2021 - IgA nephropathy (IgAN) is one of the most prevalent primary glomerulopathies in children. There are various studies investigating the efficacy of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in adults with IgAN. However, only few studies evaluated the efficacy of these medications in pediatric patients. To evaluate the efficacy and safety of ACEI/AR...

Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy.
https://doi.org/10.1007/s11481-021-10026-3 10.1136/annrheumdis-2018-213777 10.1080/0284186X.2017.1406668 10.1016/j.jtho.2019.07.033 10.1016/j.jtho.2020.11.005 10.1186/s13045-016-0309-7
Journal of Neuroimmune Pharmacology : the Official Journa... Sebbag E, Psimaras D et. al.

Oct 24th, 2021 - Immune checkpoint inhibitors (ICIs) have led to a revolution in cancer management, mainly due to lasting long-term durable responses in a subset of patients with metastatic solid tumours (Gettinger et al. in JCO 36(17):1675-1684, 2018). As immunotherapy is gradually being applied for the treatment of a large range of solid tumours, the incidence of neurological immune-related adverse events (ir...

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase ...
https://doi.org/10.1007/s11523-021-00849-8 10.1007/s00277-013-1879-x 10.4103/jomfp.JOMFP_100_17 10.1182/asheducation-2012.1.402 10.1182/hematology.2020000093 10.1111/bjh.15412 10.1200/JCO.19.00172 10.1182/blood-2017-03-769620 10.1182/blood-2014-05-577189 10.1158/2326-6066.CIR-15-0059 10.18632/oncotarget.9256 10.1016/j.annonc.2020.04.010 10.1038/s41591-020-1044-8 10.1016/S1470-2045(17)30240-1 10.1016/S1470-2045(17)30900-2 10.1186/s40425-019-0746-2 10.1001/jamaoncol.2018.5428 10.1016/S1470-2045(16)30364-3 10.1001/jamaoncol.2018.0077 10.1056/NEJMoa2002788 10.1182/blood-2015-02-629600 10.1038/leu.2014.137 10.1158/1078-0432.CCR-10-2660 10.1200/JCO.2012.48.3685 10.2217/imt-2016-0002 10.1097/HS9.0000000000000401 10.3389/fimmu.2020.00577 10.1158/2326-6066.CIR-14-0118 10.1016/S1470-2045(13)70551-5 10.1158/1078-0432.CCR-17-1922 10.1158/1078-0432.CCR-19-2973 10.1038/bcj.2014.14 10.1200/JCO.2009.23.8329 10.1016/S1470-2045(09)70003-8 10.1182/BLOOD-2018-99-114438 10.1200/JCO.2013.54.8800 10.1080/10428194.2018.1474463 10.3109/10428194.2015.1110748 10.4049/jimmunol.0901619 10.3389/fonc.2018.00351 10.1182/bloodadvances.2019000784 10.1200/JCO.2015.65.9789 10.1200/JCO.18.00766
Targeted Oncology; Hawkes EA, Phillips T et. al.

Oct 24th, 2021 - Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis despite the availability of multiple treatment options. Preliminary evidence suggests that DLBCL may be responsive to programmed death ligand 1 (PD-L1)/programmed death 1 inhibitors. The JAVELIN DLBCL study was conducted to assess whether a combination of agents could augment and sustain the anti...

Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mort...
https://doi.org/10.1016/j.intimp.2021.108242
International Immunopharmacology; Liu Y, Liu S et. al.

Oct 24th, 2021 - Immune checkpoint inhibitors (ICIs) treatment among cancer patients has been shown to have antiviral effects by reactivating exhausted T cells. However, they could also trigger inflammatory storm. Therefore, prior exposure to ICIs may influence the risk of SARS-CoV2 infection and subsequent mortality. Recent results from studies of ICIs treatment on incidence and mortality of COVID-19 are contr...

Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass sp...
https://doi.org/10.1186/s13048-021-00886-x
Journal of Ovarian Research; Franz A, Coscia F et. al.

Oct 24th, 2021 - Poly (ADP)-ribose polymerase (PARP) inhibitors have entered routine clinical practice for the treatment of high-grade serous ovarian cancer (HGSOC), yet the molecular mechanisms underlying treatment response to PARP1 inhibition (PARP1i) are not fully understood. Here, we used unbiased mass spectrometry based proteomics with data-driven protein network analysis to systematically characterize how...

Clinical and Pathological Features of Renal Presentations in Polycythemia Vera.
https://doi.org/10.1016/j.amjms.2021.10.009
The American Journal of the Medical Sciences; Yang J, Yu X et. al.

Oct 24th, 2021 - Polycythemia vera (PV) is a common type of Philadelphia chromosome-negative chronic myeloproliferative disorder. PV-associated kidney disease is rarely reported and remains poorly understood. It has been observed that chronic kidney disease could be a risk factor for poor prognosis in PV. We retrospectively analyzed the clinicopathological features of renal presentations in eight patients with ...

Is treating severe He FH so easy? A combined treatment between lipoprotein apheresis an...
https://doi.org/10.1016/j.transci.2021.103258
Transfusion and Apheresis Science : Official Journal of T... Dal Pino B, Sbrana F et. al.

Oct 23rd, 2021 - Despite advance in pharmacotherapy of lipid disorders, many heterozygous Familial Hypercholesterolemia patients do not achieve a desirable lipid target to significantly reduce the risk of atherosclerotic cardiovascular disease. The aim of the present work is to evaluate the interaction between Lipoprotein apheresis (LA) and PCSK9i in a small FH cohort in which the guidelines therapeutic target ...

Bing-Neel Syndrome: Update on the Diagnosis and Treatment.
https://doi.org/10.1016/j.clml.2021.09.014
Clinical Lymphoma, Myeloma & Leukemia; Nanah A, Al Hadidi S

Oct 23rd, 2021 - Bing-Neel syndrome (BNS) is a rare syndrome that occurs in patients with Waldenstrom macroglobulinemia and is characterized by lymphoplasmacytic infiltration into the leptomeningeal tissue and/or the central nervous system. It represents an extramedullary manifestation which may translate into various neurological symptoms. Accurate diagnosis of BNS can be established via histologic sampling an...

Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systemat...
https://doi.org/10.1007/s11523-021-00844-z 10.1016/j.jaad.2012.11.037 10.1111/j.1365-2133.2012.10830.x 10.1016/j.jaad.2017.08.059 10.1136/bmj.f6153 10.1016/0190-9622(92)70144-5 10.1016/S0360-3016(01)01656-X 10.1016/j.jaad.2017.07.048 10.1200/JCO.2010.34.1735 10.1002/cncr.31346 10.1097/DSS.0000000000000799 10.1097/COC.0000000000000088 10.1200/JCO.2019.37.15_suppl.e21033 10.1158/1535-7163.MCT-16-0665 10.1097/EDE.0b013e3181fe7825 10.1136/bmj.315.7109.629 10.1016/S0895-4356(01)00377-8 10.1056/NEJMoa1805131 10.1200/JCO.19.03054 10.1200/JCO.19.03357 10.1016/S1470-2045(19)30728-4 10.1136/jitc-2020-000775 10.1200/JCO.2019.37.15_suppl.e21015 10.1016/j.ejca.2020.01.008 10.1007/s11864-016-0408-2 10.1016/j.ejca.2020.07.029 10.3390/cancers13143547 10.1016/j.jgo.2021.02.026 10.1111/cup.13709 10.1186/s13073-017-0424-2 10.1007/s40265-020-01302-2 10.3747/co.27.6015 10.1200/JCO.2020.38.15_suppl.TPS10084 10.1200/JCO.2019.37.15_suppl.TPS9597 10.1093/annonc/mdz394.071 10.1016/j.ejca.2008.10.026 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 10.1136/jitc-2019-000146
Targeted Oncology; Mehta NK, Li AR et. al.

Oct 23rd, 2021 - Results of early trials led to FDA approval of immune checkpoint inhibitors (ICIs) for advanced and recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (CSCC). Updated data from these trials are pending and extent of survival outcomes is undetermined. The aim of this study was to assess the efficacy of ICIs in advanced CSCC, comprising locally advanced (LA), locoregionally advanced (LR...

Contemporary Approaches to the Discovery and Development of Broad-Spectrum Natural Prod...
https://doi.org/10.1021/acs.jnatprod.1c00625
Journal of Natural Products; Hanna GS, Choo YM et. al.

Oct 23rd, 2021 - The pressing need for SARS-CoV-2 controls has led to a reassessment of strategies to identify and develop natural product inhibitors of zoonotic, highly virulent, and rapidly emerging viruses. This review article addresses how contemporary approaches involving computational chemistry, natural product (NP) and protein databases, and mass spectrometry (MS) derived target-ligand interaction analys...

The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico...
https://doi.org/10.1016/j.ymthe.2021.10.014
Molecular Therapy : the Journal of the American Society O... Durdagi S, Avsar T et. al.

Oct 23rd, 2021 - Small molecule inhibitors have previously been investigated in different studies as possible therapeutics in the treatment of SARS-CoV-2. In the current drug repurposing study, we identified the leukotriene (D4) receptor antagonist Montelukast as a novel agent that simultaneously targets two important drug targets of SARS-CoV-2. We initially demonstrated the dual inhibition profile of Monteluka...

Therapeutic options for relapsed/refractory mantle cell lymphoma.
https://doi.org/10.1182/blood.2021013326
Blood Eyre TA, Cheah CY et. al.

Oct 23rd, 2021 - Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma in which immunochemotherapy +/- high dose therapy and autologous stem cell transplantation remains standard front-line therapy. Despite clear efficacy, patients envitably relapse requiring subsequent therapy. Within this review, we discuss the key therapeutic approaches in the management of patients with relapsed MCL, cov...

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
https://clinicaltrials.gov/ct2/show/NCT04566133

Oct 22nd, 2021 - Background: Among the new cases of bile tract carcinoma (BTC) that are diagnosed every year in the United States, there are approximately 6,500 cases of gallbladder carcinoma, 3,000 cases of extrahepatic cholangiocarcinoma, and 3,000 cases of intrahepatic cholangiocarcinoma. Current treatment options for patients with cholangiocarcinoma are limited and take no account of the known biological an...

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
https://clinicaltrials.gov/ct2/show/NCT01861106

Oct 22nd, 2021 - Background: Genetic and sporadic mutations on one allele of the GATA2 gene lead to a syndrome termed MonoMAC. MonoMAC is characterized by: 1) infections with Mycobacterium avium complex (MAC) and other opportunistic infections, 2) deficiency of monocytes, B-lymphocytes, and Natural Killer (NK) cells in the peripheral blood, and 3) progression to myelodysplastic syndrome (MDS), chronic myelomono...

Second-line Treatment of Primary Autoimmune Hemolytic Anemia
https://clinicaltrials.gov/ct2/show/NCT05057468

Oct 22nd, 2021 - Auto-immune hemolytic anemia (AIHA) is a heterogeneous syndrome in adults. This disease is associated with significant morbidity-mortality. First-line treatment with prolonged corticosteroid is well identified but there is not enough data about cyclosporine treatment in case of resistance or dependence on steroids. the cyclosporine showed efficacy in many immune cytopenic diseases in the light ...

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT05088889

Oct 22nd, 2021 - This is a single arm, single institution study, which aims to evaluate the efficacy and safety of combination therapy with radiosurgery nivolumab and ipilimumab as a maintenance regimen following first line induction chemotherapy in patients with metastatic pancreatic cancer. Chemotherapy will be administrated for a minimum of 4 cycles. Patients who have not progressed on chemotherapy will rece...

Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
https://clinicaltrials.gov/ct2/show/NCT05088928

Oct 22nd, 2021 - There is an increased risk of Venous and Arterial thromboembolism in COVID-19 infection. The main reason being that the novel coronavirus SARS-CoV-2 induces hyperinflammation and subsequently immunothrombolism which is wide spread in the body3. The angiotensin converting enzyme 2 (ACE2) receptor, which is utilized by the virus to infect the host, is present throughout the human body organs and ...